Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Clinical trial NCT05956041 · RECRUITING

Trial details

NCT number: NCT05956041
Sponsor: University of Michigan Rogel Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cutaneous T Cell Lymphoma Fungoides Mycosis Sezary Syndrome

Start date: 2023-12-06
Primary completion: 2026-12-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.